AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales and Marketing
September 07 2016 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today the
appointment of Tony Casciano to senior vice president of sales and
marketing for the company’s Hematology and Oncology business.
He will report to Nik Grund, AMAG’s chief commercial officer.
“Tony Casciano has a proven track record of building profitable
businesses and launching new products,” said Mr. Grund. “This
experience will be an asset to expanding AMAG’s Hematology and
Oncology unit and increasing market share both with existing
products and new business development opportunities.”
Mr. Casciano brings to AMAG more than 15 years of sales and
marketing experience and began his career at Sanofi US in 2000. He
has advanced through commercial positions of increasing
responsibility across a broad range of therapeutic areas, and most
recently served as the head of marketing for Sanofi where he led
the General Medicine division.
Mr. Casciano holds a Bachelor of Science degree in business
administration from Bridgewater State College.
Inducement Equity Awards
In connection with Mr. Casciano’s entering into employment with
AMAG, the Board of Directors of AMAG approved awards to Mr.
Casciano of (i) an option to purchase 20,000 shares of common stock
and (ii) 10,000 restricted stock units. The option will have an
exercise price equal to the closing price of AMAG's common stock on
the grant date and will be exercisable in four equal annual
installments beginning on the first anniversary of the grant date.
The option will have a ten-year term and be subject to the terms
and conditions of the stock option agreement pursuant to which the
option will be granted. The restricted stock units will vest in
three equal annual installments beginning on the first anniversary
of the grant date and will be subject to the restricted stock unit
agreement pursuant to which the restricted stock units will be
granted. These equity awards will be granted without stockholder
approval as inducements material to Mr. Casciano entering into
employment with AMAG in accordance with NASDAQ Listing Rule
5635(c)(4).
About AMAG
AMAG is a biopharmaceutical company focused on developing and
delivering important therapeutics, conducting clinical research in
areas of unmet need and creating education and support programs for
the patients and families we serve. Our products support the health
of patients in the areas of maternal health, anemia management and
cancer supportive care. Through CBR®, we also help families to
preserve newborn stem cells, which are used today in transplant
medicine for certain cancers and blood, immune and metabolic
disorders, and have the potential to play a valuable role in the
ongoing development of regenerative medicine. For additional
company information, please visit www.amagpharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws. Any statements contained herein
which do not describe historical facts, including but not limited
to statements regarding Mr. Casciano’s contributions and
responsibilities, including AMAG’s belief that Mr. Casciano’s
experience will be an asset to expanding AMAG’s Hematology and
Oncology unit and increasing market share both with existing
products and new business development opportunities are
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those
identified in AMAG’s Securities and Exchange Commission (SEC)
filings, including AMAG’s Annual Report on Form 10-K for the year
ended December 31, 2015, its Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2016 and June 30, 2016 and subsequent
filings with the SEC. We caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc. CBR® is a registered trademark
of CBR Systems, Inc.
AMAG Pharmaceuticals, Inc. Contact:
Maryann Cimino
Manager, Corporate Communications & External Affairs
617-498-3375
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024